Literature DB >> 15722574

Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

Rajesh Kannangai1, Jianzhou Wang, Qiong Z Liu, Fikret Sahin, Michael Torbenson.   

Abstract

BACKGROUND: Survivin is a recently described anti-apoptotic protein that is suppressed by wild-type p53 and is overexpressed in 41-70% of hepatocellular carcinomas from Asia. Two alternatively spliced transcripts have also been described: anti-apoptotic survivin-DeltaEx3 and non-anti-apoptotic survivin-2B. Survivin splice variant expression has not been studied in HCC, and little is known about survivin expression in hepatocellular carcinomas arising in other parts of the world, where risk factors are often different than they are in Asia. AIM OF THE STUDY: We studied survivin mRNA and protein expression in a United States cohort of hepatocellular carcinomas and correlated the findings with p53 immunopositivity.
METHODS: RT-PCR was performed for survivin, survivin-2B, and survivin-DeltaEx3 in 20 HCCs and one intrahepatic cholangiocarcinoma. Expression levels of total survivin were evaluated with real-time PCR. Protein expression was examined by immunohistochemistry.
RESULTS: Survivin was the major transcript, and all transcripts were present in all normal and neoplastic tissues; 11/20 (55%) HCCs and the one cholangiocarcinoma showed twofold or greater overexpression of survivin. Next, we examined survivin and p53 protein expression by immunohistochemistry on a separate series of 79 HCC, 13 fibrolamellar carcinomas, and 15 hepatic adenomas; 14/79 (17%) HCC, but none of the fibrolamellar carcinomas or hepatic adenomas, showed survivin protein overexpression, and 25/79 HCC (32%) showed abnormal nuclear accumulation of p53, which correlated with increased survivin expression.
CONCLUSIONS: All three survivin transcripts are present in normal liver and HCC. Survivin is the dominant transcript in HCC and is overexpressed in 55% of cases. Survivin protein overexpression is associated with aberrant p53 nuclear positivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722574     DOI: 10.1385/IJGC:35:1:053

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  22 in total

Review 1.  Survivin study: what is the next wave?

Authors:  Fengzhi Li
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

2.  Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway.

Authors:  Michael Torbenson; Jae-Hyuk Lee; Michael Choti; Wesley Gage; Susan C Abraham; Elizabeth Montgomery; John Boitnott; Tsung-Teh Wu
Journal:  Mod Pathol       Date:  2002-03       Impact factor: 7.842

3.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.

Authors:  C Mahotka; M Wenzel; E Springer; H E Gabbert; C D Gerharz
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Immunohistochemical study of P53, PCNA and AFP in hepatocellular carcinoma, a comparison between Indonesian and Japanese cases.

Authors:  W Marwoto; U A Miskad; N C Siregar; R A Gani; U Boedihusodo; S Nurdjanah; P Boedi; H A Hasan; N Akbar; H M Noer; Y Hayashi
Journal:  Kobe J Med Sci       Date:  2000-10

5.  Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.

Authors:  Masahide Ikeguchi; Tsuyoshi Ueta; Yoshiaki Yamane; Yasuaki Hirooka; Nobuaki Kaibara
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

6.  Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.

Authors:  D Grossman; P J Kim; O P Blanc-Brude; D E Brash; S Tognin; P C Marchisio; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  Expression of survivin during liver regeneration.

Authors:  Masatoshi Deguchi; Katsuya Shiraki; Hidekazu Inoue; Hiroshi Okano; Takeshi Ito; Takenari Yamanaka; Kazushi Sugimoto; Takahisa Sakai; Shigeru Ohmori; Kazumoto Murata; Akihiro Furusaka; Hisashi Hisatomi; Takeshi Nakano
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

8.  Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?

Authors:  Woo Sung Moon; Andrzej S Tarnawski
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

9.  Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors.

Authors:  Chung J Hung; David G Ginzinger; Raza Zarnegar; Hajime Kanauchi; Mariwil G Wong; Electron Kebebew; Orlo H Clark; Quan-Yang Duh
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

10.  Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression.

Authors:  A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

View more
  15 in total

1.  Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.

Authors:  Jiahua Jiang; Veronika Slivova; Andrej Jedinak; Daniel Sliva
Journal:  Clin Exp Metastasis       Date:  2011-12-14       Impact factor: 5.150

Review 2.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

3.  BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Izidor Kern; Andrej Cör
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-23       Impact factor: 4.553

4.  The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Authors:  Anna G Antonacopoulou; Konstantina Floratou; Vasiliki Bravou; Anastasia Kottorou; Fotinos-Ioannis Dimitrakopoulos; Stella Marousi; Michalis Stavropoulos; Angelos K Koutras; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

5.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

6.  Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area.

Authors:  Andra-Iulia Suceveanu; Ioan Sergiu Micu; Gabriela-Izabela Baltatescu; Lucian Cristian Petcu; Nicolae Dobrin; Costel Brinzan; Cornelia Nitipir; Laura Mazilu; Florin Botea; Vlad Herlea; Felix Voinea; Adrian Paul Suceveanu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

Review 7.  Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Authors:  Natale D'Alessandro; Paola Poma; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

8.  Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma.

Authors:  Lili Guo; Min Tang; Lifang Yang; Lanbo Xiao; Ann M Bode; Lili Li; Zigang Dong; Ya Cao
Journal:  Int J Mol Med       Date:  2012-01-17       Impact factor: 4.101

9.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.

Authors:  Claudia Augello; Luca Caruso; Marco Maggioni; Matteo Donadon; Marco Montorsi; Roberto Santambrogio; Guido Torzilli; Valentina Vaira; Caterina Pellegrini; Massimo Roncalli; Guido Coggi; Silvano Bosari
Journal:  BMC Cancer       Date:  2009-04-27       Impact factor: 4.430

Review 10.  Immunotherapy for liver tumors: present status and future prospects.

Authors:  Pablo Matar; Laura Alaniz; Viviana Rozados; Jorge B Aquino; Mariana Malvicini; Catalina Atorrasagasti; Manuel Gidekel; Marcelo Silva; O Graciela Scharovsky; Guillermo Mazzolini
Journal:  J Biomed Sci       Date:  2009-03-06       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.